+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
MALE
ID03541928

Phase II Study of HSV-tk and Valacyclovir Gene Therapy Combined with Hormone Therapy, Radiotherapy, and Surgery for High-Risk Prostate Cancer

Led by The Methodist Hospital Research Institute · Updated on 2021-04-06

60

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of a gene therapy called HSV-tk combined with valacyclovir, alongside androgen deprivation therapy, brachytherapy, external beam radiotherapy, and prostatectomy in men with previously untreated high-risk prostate cancer. This phase II study aims to understand how well this combination controls the disease and its side effects. Participants will receive the HSV-tk gene therapy injected into the prostate twice, on day 0 and day 30. Valacyclovir will be taken orally three times daily for two separate 14-day periods. They will also receive daily Bicalutamide tablets combined with monthly Leuprolide acetate injections for two months. Around day 60, participants will undergo high dose rate brachytherapy using needle catheters and radiation. Approximately 2 to 3 weeks after completing radiotherapy, patients will have a radical prostatectomy surgery. Throughout the study, participants will be closely monitored with blood tests, digital rectal exams, and prostate biopsies to assess cancer response and immune effects. Researchers will track prostate specific antigen PSA levels over time and watch for side effects using standardized scoring systems. The main outcome is the 5-year biochemical disease-free survival rate. Safety and overall survival will also be followed for up to five years after treatment.

CONDITIONS

Brief Title

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

Research Team

E

Emily Hsiao, Ph.D.

C

Christine O'Reilly

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here